Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs HCA Health Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.78 (market cap $3.06B), while HCA Health Inc trades at $450.18 (market cap $96.35B). The key difference: HCA Health Inc is far larger — about 31.5× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and HCA Health Inc pays a 0.7% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days and HCA Health Inc for 76 Days on average.
| FLRN | HCA | |
|---|---|---|
Market Cap | $3.06B | $96.35B |
Volume | 6,296,473 | 1,079,453 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $545.13 |
52-Week Low | $30.65 | $361.32 |
Typical Hold Time | 16 Days | 76 Days |
Enterprise Value | — | $146.88B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.77 with minimal daily movement (+0.07%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent quarterly dividends of $0.11, with recent institutional buying interest from Concurrent Investment Advisors. Current market focus centers on floating rate bonds' performance amid rising interest rate expectations.
FLRN offers exposure to investment-grade floating rate bonds with near-zero duration, positioning it as a potential hedge against rate hikes. Key risks include concentrated financial sector exposure and sensitivity to credit spread changes. The ETF's structure provides income stability but faces headwinds from potential economic slowdowns affecting corporate bond markets.
HCA Healthcare trades at $451.09, up 2.71% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q4 2025 and Q1-Q2 2026 exceeding expectations, supported by robust revenue growth from $70.6B in 2024 to $75.6B in 2025. Valuation metrics remain attractive with P/E of 14.92 and P/S of 1.31, while technical indicators signal bullish momentum above key support levels.
The outlook remains positive with 63% analyst buy ratings and $461.12 consensus target, though legal investigations and high debt levels pose risks. Revenue growth and operational efficiency provide upside potential, but investors should monitor regulatory developments and debt management closely given the 80.9% debt-to-asset ratio in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
